SecProbe.io

CORRESP
1
filename1.htm

CORRESP

 Tandem Diabetes Care, Inc.

11045 Roselle Street

 San
Diego, CA 92121

 October 24, 2013

SUBMITTED VIA EDGAR

 Securities and Exchange Commission

 Division of Corporation Finance

 100 F Street, N.E.

Washington, D.C. 20549

 Attention: Mary Beth Breslin, Esq.

Re:
Tandem Diabetes Care, Inc.

Registration Statement on Form S-1

Filed October 7, 2013

File No. 333-191601

Responses to Staff comments made by letter dated October 15, 2013

 Dear Ms. Breslin:

Set forth below are the responses of Tandem Diabetes Care, Inc., a Delaware corporation (the “Company”), to comments made by
the staff of the Securities and Exchange Commission (the “Staff”) by letter dated October 15, 2013 (the “Comment Letter”) in connection with the Company’s Registration Statement on Form S-1 (File
No. 333-191601), which the Company initially filed on October 7, 2013 (the “Original Registration Statement”). Concurrent with the submission of this response letter, the Company is filing Amendment No. 1 to the
Original Registration Statement (as so amended, the “Registration Statement”). The Registration Statement has been updated in response to Staff comments made in the Comment Letter. In addition, the Company has revised the
Registration Statement to update other disclosures, including the presentation of financial results as of and for the nine months ended September 30, 2013.

The Company’s responses are preceded by a reproduction of the corresponding Staff comments as set forth in the Comment Letter. To the
extent applicable, each response contains a reference to the page number(s) where the responsive information may be found in the Registration Statement.

 Securities and Exchange Commission

Tandem Diabetes Care, Inc.

 Registration Statement on Form S-1
(File No. 333-191601)

 October 24, 2013

  Page
 2

 Artwork

1.
We refer to prior comment 1 and your revisions on the second page of graphics. We note that the text above the display monitor explains to investors that the center graphic is your “t:slim Insulin Pump.”
Accordingly, the icons and accompanying text do not appear necessary to explain your visuals. Additionally, it is not appropriate to highlight “key product features” in your artwork without balancing the presentation to highlight key
product limitations and/or competitive disadvantages. Please revise your graphics accordingly.

Company Response:

 The Company has revised the artwork on the second page to
remove the icons and accompanying text surrounding the t:slim pump.

 The Market, page 2

2.
We note your response to prior comment 10; however, the report does not clarify how the 5% estimate was calculated or whether any assumptions were necessary to derive the figure. Please provide us with this information.
To the extent assumptions were used, please revise your disclosure where you cite the figure to provide the necessary context. For instance, if the estimate does not reflect any patients who return to injections or otherwise stop using a pump,
revise to so state.

Company Response:

 When the Company submitted its responses to comments made by
the Staff in its letter dated September 6, 2013, the Company supplementally provided the Staff, pursuant to Rule 418 under the Securities Act of 1933, as amended (the “Securities Act”), a support binder (the “Support
Binder”), which provided certain backup and support information requested by the Staff. The Support Binder included a report issued by Close Concerns, Inc. (the “Close Concerns Report”), an independent consulting and
information publishing company that provides diabetes advisory services (“Close Concerns”).

 The Close Concerns Report
specifically identifies the estimated 5% annual increase estimate on page 2 thereof. The Company understands that Close Concerns derived this amount by simply dividing (x) 25,000, which represents Close Concern’s estimate of the number of
people in the U.S. who begin using insulin pump therapy each year, by (y) 500,000, which represents the high end of Close Concern’s estimated range of the aggregate number of people in the U.S. who use insulin pumps (25,000 / 500,000 =
5%). Notably, Close Concerns did not utilize the low end of the estimated range of the number of insulin pump users in the U.S. (450,000) in performing the estimated growth percentage as this would have resulted in a larger growth rate than the
5% amount provided in the Close Concerns Report.

 The Close Concerns Report does not cite, and the Company is not aware of, any additional
assumptions relied upon in calculating the estimated growth rate.

 Securities and Exchange Commission

Tandem Diabetes Care, Inc.

 Registration Statement on Form S-1
(File No. 333-191601)

 October 24, 2013

  Page
 3

 Sales and Marketing, page 76

3.
We note your revised disclosure identifying your 10% customers and refer to Schedule 7.14 to Exhibit 10.2, which indicates that you have distribution agreements with both 10% customers. Please file these agreements as
material contracts or explain why you believe they are not material.

Company Response:

 The Company respectfully submits that it should not be
required to file any of its distribution agreements as material contracts as none of the agreements individually is material to the Company’s business. As disclosed in the “Business – Sales and Marketing” section of the
Registration Statement, as of September 30, 2013, the Company had entered into separate agreements with approximately 27 independent distributors. These agreements are all non-exclusive arrangements, and have one-year terms with automatic
one-year renewal terms. In each case, either party may opt out of any automatic renewal by providing prior notice. The Company also expects to enter into additional agreements with other independent distributors in the near-term. Given the volume of
independent distributor agreements that it has entered into, the regularity with which it pursues further opportunities to enter into similar agreements, as well as the short-term, non-exclusive nature of the business arrangements, the Company
believes the independent distributor agreements are entered into, and will continue to be entered into, in the ordinary course of its business. As a result, the Company respectfully submits that the agreements should be exempt from the exhibit
filing requirements pursuant to Item 601(b)(10)(i) of Regulation S-K.

 In addition, although the Company has disclosed that certain
independent distributors have historically accounted for greater than 10% of the Company’s sales, the percentage of Company sales that are derived from individual distributor relationships has already decreased since the commercialization of
t:slim in August 2012. For example, RGH Enterprises, Inc. (“RGH”) accounted for 19.3% of the Company’s sales for the period ended December 31, 2012, but more recently accounted for only 17.2% of the Company’s sales
for the nine month period ended September 30, 2013, as disclosed in the Registration Statement. Similarly, Solara Medical Supplies, Inc. (“Solara”) accounted for 15.7% of the Company’s sales for the period ended
December 31, 2012, but more recently accounted for less than 10% of the Company’s sales for the nine month period ended September 30, 2013. For the nine month period ended September 30, 2013, another independent distributor, CCS
Medical, Inc. (“CCS”), accounted for 11.7% of the Company’s sales. The Company also believes it is important to note that, in addition to the sales generated through RGH and CCS, for the nine month period ended
September 30, 2013, there were five other significant customers that each accounted for between 5% and 10% of the Company’s total sales, which further demonstrates the broad distribution of the Company’s sales through multiple
channels.

 The decreases in the percentages of Company sales made to particular distributors, such as RGH and Solara, are attributable to
both the large and growing number of independent

 Securities and Exchange Commission

Tandem Diabetes Care, Inc.

 Registration Statement on Form S-1
(File No. 333-191601)

 October 24, 2013

  Page
 4

distributors with which the Company has entered into distribution agreements (which necessarily divide total Company sales made to distributors by a larger number of distributors) as well as the
Company’s increased focus on generating sales directly through its sales, clinical and marketing team (which has the effect of reducing the percentage of sales to independent distributors as a function of total Company sales, further reducing
the percentage of Company sales to any particular distributor). As a result of these and other factors, the Company believes that the percentage of its total sales that are made to independent distributors will continue to decrease over time.
Accordingly, the Company does not believe that its business is or will be substantially dependent on any single independent distributor agreement for purposes of Item 601(b)(10)(ii)(B) of Regulation S-K. In addition, the Company believes that
none of the individual agreements are otherwise material to an investor’s understanding of the Company’s business.

 The Company
also notes that it anticipates that the percentage of its total sales made to any individual independent distributor will vary year-to-year, and even from quarter-to-quarter, as illustrated by the decreases described above for RGH and Solara and the
increase for CCS. For this reason, as well as the broad distribution of sales among various independent distributors as described above, the Company believes that placing undue focus on any particular distributor or group of distributors would be
inappropriate and potentially even misleading to investors.

 Finally, although the distribution agreements were identified on Schedule 7.14
to Exhibit 10.2, the Company respectfully notes to the Staff that the Company’s representations and warranties contained in Exhibit 10.2 were not intended to be treated as categorical statements of fact, but rather as a way of allocating the
risk to one of the parties if those statements prove to be inaccurate. In disclosing those agreements on Schedule 7.14 to Exhibit 10.2, the Company applied contract standards of “materiality” that are different from the concept of
“materiality” under applicable securities laws.

 Notwithstanding the foregoing, in response to the Staff’s comment, the
Company has supplemented its disclosure in the “Business – Sales and Marketing” section of the Registration Statement to inform investors of the non-exclusive nature of the independent distributor agreements as well as the annual
termination rights generally available to both the Company and the independent distributor pursuant to those agreements.

 Manufacturing and Quality
Assurance, page 79

4.
With a view to disclosure concerning your manufacturing, please tell us about the nature of the OEM Agreement and the Manufacturing Agreement which are referenced in items 6 and 33 in Schedule 7.14 to Exhibit 10.2.

Company Response:

 The Company believes that each of the OEM Agreement and the
Manufacturing Agreement referenced in the Staff’s comment were entered into in the ordinary course of the Company’s business. Furthermore, the Company does not believe that its business is or will be substantially dependent on either the
OEM Agreement or the Manufacturing Agreement.

 Securities and Exchange Commission

Tandem Diabetes Care, Inc.

 Registration Statement on Form S-1
(File No. 333-191601)

 October 24, 2013

  Page
 5

 The OEM Agreement
relates to the Company’s purchase of infusion sets that are sold to customers separate from the t:slim pump. The infusion sets that are the subject of the OEM Agreement are only one of several brands sold by the Company. As disclosed in the
“Management’s Discussion and Analysis of Financial Condition and Results of Operations” section of the Registration Statement, the Company’s sales of all pump-related supplies and accessories in the aggregate, including infusion
sets, cartridges, belt clips and other accessories, comprised only approximately 9.0% of the Company’s sales for the nine month period ended September 30, 2013, of which sales of infusion sets that we supplied under the OEM Agreement
comprised only a small portion. Due to both the relatively small amount of sales generated from infusion sets that the Company purchases under the OEM Agreement, and the fact that the Company also sells several other brands of infusion sets under
different contractual arrangements, the Company’s business is not substantially dependent on the OEM Agreement or the products that are the subject of the agreement for purposes of Item 601(b)(10)(ii)(B) of Regulation S-K. In addition, the
Company believes that the agreement is not otherwise material to an investor’s understanding of the Company’s business.

 The
Manufacturing Agreement relates to the manufacture and testing of a component of the t:slim pump. However, the agreement does not contain any purchase obligations or commitments by the Company. Purchase commitments are subject to separate purchase
orders, and only to the extent that the Company actually places any orders will the terms of the agreement apply. In addition, the agreement is subject to termination by the Company upon short notice and without penalty. The Company believes that it
could identify alternative suppliers within the notice period if necessary. Due to the lack of minimum purchase commitments and the fact that the Company believes it can readily identify replacement suppliers, the Company’s business is not
substantially dependent on the agreement or the components that are the subject of the agreement for purposes of Item 601(b)(10)(ii)(B) of Regulation S-K. In addition, the Company believes that the agreement is not otherwise material to an
investor’s understanding of the Company’s business.

 Finally, the Company respectfully submits that, although the OEM Agreement
and the Manufacturing Agreement were identified on Schedule 7.14 to Exhibit 10.2, the considerations discussed in the Company’s response to Staff comment 3 in relation to the representations and warranties contained in Exhibit 10.2 apply
equally in this context.

 For the foregoing reasons, the Company respectfully submits that it should not be required to revise the
Registration Statement in response to the Staff comment.

 Intellectual Property, page 81

5.
We note your response to prior comment 33. Given the size of the license fee payment relative to your revenues and your operating and net losses, it is not clear how you determined that the agreement is not required to
be disclosed and filed as an exhibit to your registration statement. Please revise to disclose the identity of the unnamed party and file the agreement.

 Securities and Exchange Commission

Tandem Diabetes Care, Inc.

 Registration Statement on Form S-1
(File No. 333-191601)

 October 24, 2013

  Page
 6

Company Response:

 The third paragraph of the “Business – Intellectual
Property” section and the second paragraph of the “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Capitalized Intellectual Property” section have been revised to provide the identity
of the party to the agreement. The redacted version of the agreement has also been filed as Exhibit 10.20 to the Registration Statement. The Company is seeking to omit confidential portions of the agreement pursuant to Rule 406 promulgated under the
Securities Act.

 Market Comparisons, page 99

6.
We note your response to prior comment 36; however, to the extent that you benchmark total compensation to that of the companies contained in the surveys you or your consultants used, please revise your disclosure to
identify the surveys used and their components, including component companies. Refer to Item 402(b)(2)(xiv) of Regulation S-K.

Company Response:

 The C